CSPG4 and metastatic melanoma: Overall, the results outlined in this study provide strong translational rationale for the design of clinical trials investigating CSPG4-CAR.CIK within the challenging setting of patients with metastatic melanoma who do not respond or relapse to treatment with immune checkpoint inhibitors.